Literature DB >> 29575185

Identification of VIM-2 metallo-β-lactamase-producing Pseudomonas aeruginosa isolated from dogs with pyoderma and otitis in Korea.

Jae-Eun Hyun1, Tae-Ho Chung2, Cheol-Yong Hwang1.   

Abstract

BACKGROUND: Pseudomonas aeruginosa is a challenging pathogen cultured from cases of acute and chronic canine otitis and sometimes in cases of deep pyoderma. The spread of antimicrobial resistance, especially carbapenem resistance, is a serious therapeutic challenge worldwide. HYPOTHESIS/
OBJECTIVES: To investigate the identification and characterization of resistant P. aeruginosa clinical canine isolates. MATERIALS: Clinical isolates (n = 80) were collected from dogs with pyoderma (n = 18) and otitis (n = 62) in Korea.
METHODS: Antimicrobial susceptibility was determined using agar dilution and using Clinical and Laboratory Standards Institute guidelines for recording susceptibility for human Pseudomonas isolates; genetic relatedness of isolates was investigated by multilocus sequence typing (MLST) and SpeI macrorestriction analysis. The class 1 integrons were amplified and sequenced using primer walking.
RESULTS: Most isolates were susceptible to colistin (97.5%), polymyxin B (96.3%), ciprofloxacin (81.3%) and meropenem (80.0%); whereas resistance to aztreonam (80%), piperacillin (52.5%), piperacillin/tazobactam (41.3%) and cefepime (37.5%) was high; 12 carbapenem-nonsusceptible isolates (15%) were detected. MLST revealed 45 different sequence types (STs) and macrorestriction analysis detected 55 distinct pulsotypes (PTs), which were divided into 25 clonal groups. Among carbapenem-nonsusceptible isolates, 10 (83.3%) were VIM-2-producing strains. Nine VIM-2-producing isolates were identified as ST1047 and harboured the same 2.8 kb class 1 integron. One remaining isolate was ST1203 with 2.1 kb class 1 integron. CONCLUSIONS AND CLINICAL IMPORTANCE: This study demonstrated the diversity of the phenotype and genotype of clinical P. aeruginosa isolates from dogs with pyoderma and otitis. The identification of VIM-2-producing P. aeruginosa in dogs is alarming and warrants further surveillance.
© 2018 ESVD and ACVD.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29575185     DOI: 10.1111/vde.12534

Source DB:  PubMed          Journal:  Vet Dermatol        ISSN: 0959-4493            Impact factor:   1.589


  6 in total

1.  Molecular Characterization of Multidrug-Resistant Pseudomonas aeruginosa Isolates in Hospitals in Myanmar.

Authors:  Tatsuya Tada; Tomomi Hishinuma; Shin Watanabe; Hiroki Uchida; Mari Tohya; Kyoko Kuwahara-Arai; San Mya; Khin Nyein Zan; Teruo Kirikae; Htay Htay Tin
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 2.  Companion Animals-An Overlooked and Misdiagnosed Reservoir of Carbapenem Resistance.

Authors:  Joana Moreira da Silva; Juliana Menezes; Cátia Marques; Constança Ferreira Pomba
Journal:  Antibiotics (Basel)       Date:  2022-04-17

3.  Effective treatment and decolonization of a dog infected with carbapenemase (VIM-2)-producing Pseudomonas aeruginosa using probiotic and photodynamic therapies.

Authors:  Fábio P Sellera; Miriam R Fernandes; Caetano P Sabino; Laura M de Freitas; Luciano C B A da Silva; Fabio C Pogliani; Martha S Ribeiro; Michael R Hamblin; Nilton Lincopan
Journal:  Vet Dermatol       Date:  2019-01-03       Impact factor: 1.589

4.  Occurrence, antimicrobial susceptibility, and pathogenic factors of Pseudomonas aeruginosa in canine clinical samples.

Authors:  Jasmine Hattab; Francesco Mosca; Cristina Esmeralda Di Francesco; Giovanni Aste; Giuseppe Marruchella; Pierluigi Guardiani; Pietro Giorgio Tiscar
Journal:  Vet World       Date:  2021-04-23

5.  Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): antimicrobial-resistant Pseudomonas aeruginosa in dogs and cats.

Authors:  Søren Saxmose Nielsen; Dominique Joseph Bicout; Paolo Calistri; Elisabetta Canali; Julian Ashley Drewe; Bruno Garin-Bastuji; José Luis Gonzales Rojas; Christian Gortázar; Mette Herskin; Virginie Michel; Miguel Ángel Miranda Chueca; Barbara Padalino; Paolo Pasquali; Helen Clare Roberts; Hans Spoolder; Karl Ståhl; Antonio Velarde; Arvo Viltrop; Christoph Winckler; Francesca Baldinelli; Alessandro Broglia; Lisa Kohnle; Julio Alvarez
Journal:  EFSA J       Date:  2022-05-03

6.  Pseudomonas aeruginosa biofilm dispersion by the mouse antimicrobial peptide CRAMP.

Authors:  Yang Zhang; Peng Cheng; Shiyuan Wang; Xiaofen Li; Lianci Peng; Rendong Fang; Jing Xiong; Hui Li; Cui Mei; Jiye Gao; Zhenhui Song; Dengfeng Xu; Lizhi Fu; Chenghong Li; Xueqing Wu; Yuzhang He; Hongwei Chen
Journal:  Vet Res       Date:  2022-10-08       Impact factor: 3.829

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.